$2.46
2.38% today
Nasdaq, Aug 25, 03:49 pm CET
ISIN
US0144421072
Symbol
ALEC

Alector, Inc. Stock price

$2.52
+0.80 46.51% 1M
+0.74 41.57% 6M
+0.63 33.33% YTD
-2.55 50.30% 1Y
-8.79 77.72% 3Y
-10.29 80.33% 5Y
-14.11 84.85% 10Y
-14.11 84.85% 20Y
Nasdaq, Closing price Fri, Aug 22 2025
+0.25 11.01%
ISIN
US0144421072
Symbol
ALEC
Industry

Key metrics

Basic
Market capitalization
$255.1m
Enterprise Value
$-42.7m
Net debt
positive
Cash
$307.3m
Shares outstanding
101.2m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
3.1 | 16.3
EV/Sales
negative | negative
EV/FCF
0.2
P/B
3.6
Financial Health
Equity Ratio
27.1%
Return on Equity
-93.9%
ROCE
-49.4%
ROIC
1,939.1%
Debt/Equity
0.1
Financials (TTM | estimate)
Revenue
$81.1m | $15.6m
EBITDA
$-123.5m | $-223.6m
EBIT
$-134.5m | $-204.3m
Net Income
$-115.3m | $-158.9m
Free Cash Flow
$-216.0m
Growth (TTM | estimate)
Revenue
46.8% | -84.4%
EBITDA
32.0% | -64.2%
EBIT
28.2% | -40.9%
Net Income
28.3% | -33.4%
Free Cash Flow
0.8%
Margin (TTM | estimate)
Gross
-
EBITDA
-152.2% | -1,428.9%
EBIT
-165.8%
Net
-142.1% | -1,015.3%
Free Cash Flow
-266.3%
More
EPS
$-1.2
FCF per Share
$-2.1
Short interest
7.1%
Employees
238
Rev per Employee
$420.0k
Show more

Is Alector, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,019 stocks worldwide.

Alector, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

14 Analysts have issued a Alector, Inc. forecast:

11x Buy
79%
1x Hold
7%
2x Sell
14%

Analyst Opinions

14 Analysts have issued a Alector, Inc. forecast:

Buy
79%
Hold
7%
Sell
14%

Financial data from Alector, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
81 81
47% 47%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 58 58
1% 1%
71%
- Research and Development Expense 156 156
16% 16%
192%
-123 -123
32% 32%
-152%
- Depreciation and Amortization 11 11
92% 92%
14%
EBIT (Operating Income) EBIT -135 -135
28% 28%
-166%
Net Profit -115 -115
28% 28%
-142%

In millions USD.

Don't miss a Thing! We will send you all news about Alector, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Alector, Inc. Stock News

Neutral
Seeking Alpha
16 days ago
Alector, Inc. (NASDAQ:ALEC ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Arnon Rosenthal - Co-Founder, CEO & Director Giacomo Salvadore - Chief Medical Officer Katie Hogan - Senior Director of Corporate Communication & Investor Relations Neil Berkley - Interim CFO & Chief Business Officer Saraswati Kenkare-Mitra - President and Head of Research & Development ...
Neutral
The Motley Fool
18 days ago
Alector (ALEC) Q2 Revenue Falls 48%
Neutral
GlobeNewsWire
18 days ago
On track to report topline data by mid-Q4 2025 from the pivotal INFRONT-3 Phase 3 clinical trial of latozinemab in FTD-GRN, a severe, rare form of dementia with no approved treatments Ongoing Phase 2 PROGRESS-AD trial of AL101 in early Alzheimer's disease expected to complete in 2026 Continuing to progress Alector Brain Carrier programs, including the company's anti-amyloid beta antibody, engin...
More Alector, Inc. News

Company Profile

Alector, Inc. operates as a clinical-stage biopharmaceutical company. It develops therapeutics for the treatment of neurodegenerative diseases including frontotemporal dementia (FTD), Alzheimer's disease, and Parkinson's disease. The company was founded by Asa Abeliovich, Errik B. Anderson, Tillman U. Gerngross, and Arnon Rosenthal in May 2013 and is headquartered in South San Francisco, CA.

Head office United States
CEO Arnon Rosenthal
Employees 238
Founded 2013
Website alector.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today